All told, 70% of Botox sales were in the US, where the therapeutic/cosmetic split was 64/36; 30% of Botox sales were ex-US, where the therapeutic/cosmetic split was 38/62.
†Includes $17.3M sales for hyperhidrosis.
*The large 2Q18 increase relative to 1Q18 was expected; for cosmetic indications, the second and fourth quarters are seasonally stronger than the first and third quarters.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.